Tuhura Biosciences, Inc. (HURA) - Form 8-K Summary
Business Context and Reporting Period
Date of Report: December 9, 2025
Company: Tuhura Biosciences, Inc.
Event: Entry into a Material Definitive Agreement for a Registered Direct Offering.
The Company entered into a Securities Purchase Agreement to sell common stock and warrants in a registered direct offering. The transaction is structured to close in three tranches.
Key Financial Metrics and Transaction Details
| Metric | Value |
|---|---|
| Offering Price | $1.65 per Share (plus accompanying warrants) |
| Total Shares to be Issued | 9,462,423 Common Shares |
| Total Warrants Issued | 18,924,846 (9,462,423 Series A + 9,462,423 Series B) |
| Warrant Exercise Price | $1.95 per share |
| Expected Gross Proceeds | ~$15.6 Million Total ($8.6M First Closing, $5M Second, $2M Third) |
| Placement Agent Fees | 7.0% of First Closing proceeds; 2.0% of Second/Third Closing proceeds |
| Placement Agent Warrants | 283,873 shares (3.0% of offering) at $2.0625 exercise price |
Material Changes and Transaction Structure
- Tranche Structure:
- First Closing: 5,219,999 shares issued immediately upon execution.
- Second Closing: 3,030,303 shares to K&V Investment One LLC by January 30, 2026.
- Third Closing: 1,212,121 shares to K&V Investment One LLC by February 27, 2026.
- Use of Proceeds: Primarily for working capital, general corporate purposes, and satisfaction of a $3.4 million bridge note obligation to the Matthew Nachtrab Revocable Trust (net of $1.75 million invested by the lender into the offering).
- Lock-Up Agreements: Directors and officers are restricted from selling securities for 30 days post-closing. The Company is restricted from issuing variable rate transactions for 6 months.
Outlook, Risks, and Contingencies
Management Commentary: The Company intends to utilize the net proceeds to strengthen its liquidity position and retire specific debt obligations. The offering was registered under a Form S-3 filed on November 3, 2025.
Risks and Contingencies:
- Actual proceeds may differ from estimates due to placement agent fees and offering expenses.
- Forward-looking statements regarding the timing of closings and use of proceeds are subject to risks including liquidity needs, capital market conditions, and the ability to raise further capital.
- Dilution to existing shareholders due to the issuance of new shares and warrants.
Investor Verification Checklist
- Verify the final closing dates for the Second and Third tranches with K&V Investment One LLC.
- Confirm the exact net proceeds after deducting the 7% and 2% placement fees and legal expenses.
- Review the specific terms of the $3.4 million bridge note being retired to understand the impact on the balance sheet.
- Monitor the dilution impact of the 18.9 million warrants exercisable at $1.95.
- Check for any subsequent filings regarding the completion of the First Closing.